Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice.
The effectiveness of genetic engineering with lentivectors to protect transplanted cells from allogeneic rejection was examined using, as a model, type 1 diabetes treatment with beta-cell transplantation, whose widespread use has been limited by the requirement for sustained immunosuppressive treatment to prevent graft rejection. We examined whether lentivectors expressing select immunosuppressive proteins encoded by the adenoviral genome early region 3 (AdE3) would protect transplanted beta-cells from an alloimmune attack. The insulin-producing beta-cell line beta TC-tet (C3HeB/FeJ-derived) was transduced with lentiviruses encoding the AdE3 proteins gp19K and RID alpha/beta. The efficiency of lentiviral transduction of beta TC-tet cells exceeded 85%. Lentivector expression of gp19K decreased surface class I major histocompatibility complex expression by over 90%, whereas RID alpha/beta expression inhibited cytokine-induced Fas upregulation by over 75%. beta TC-tet cells transduced with gp19K and RID alpha/beta lentivectors, but not with a control lentivector, provided prolonged correction of hyperglycemia after transplantation into diabetic BALB/c severe combined immunodeficient mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice. Thus, genetic engineering of beta-cells using gp19K- and RID alpha/beta-expressing lentiviral vectors may provide an alternative that has the potential to eliminate or reduce treatment with the potent immunosuppressive agents necessary at present for prolonged engraftment with transplanted islets.
Kojaoghlanian
T
T
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Joseph
A
A
Follenzi
A
A
Zheng
J H
JH
Leiser
M
M
Fleischer
N
N
Horwitz
M S
MS
DiLorenzo
T P
TP
Goldstein
H
H
D017503:Adenovirus E3 Proteins / Q000235:genetics / Q000276:immunology; D017456:Adenovirus Early Proteins / Q000235:genetics / Q000276:immunology; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000628:therapy*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy*; D004195:Disease Models, Animal; D005260:Female; D005818:Genetic Engineering / Q000379:methods*; D005822:Genetic Vectors; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D007108:Immune Tolerance; D050417:Insulin-Secreting Cells / Q000276:immunology*; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D016086:Lentivirus / Q000235:genetics; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D014161:Transduction, Genetic
D017503:Adenovirus E3 Proteins; D017456:Adenovirus Early Proteins; C084390:E3 glycoprotein 19k, Adenovirus type 7